National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

For the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa® administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.

Rapid Review

Commenced Completed Outcome
13/03/2013 16/04/2013 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
26/09/2013 30/12/2013 Reimbursement not recommended at the submitted price


December 2015

The HSE has approved reimbursement following confidential price negotiations.

 The HSE has now requested a full HTA for this product 25th June 2018
Full pharmacoeconomic assessment commissioned by HSE 25/06/2018
Pre-submission consultation with Applicant 05/07/2018
Submission received from Applicant 10/09/2018
Preliminary review sent to Applicant 05/12/2018
NCPE assessment re-commenced 14/01/2019
Preliminary review II sent to Applicant 30/01/2019
NCPE assessment re-commenced 15/02/2019
Factual accuracy sent to Applicant 19/03/2019
NCPE assessment re-commenced 02/04/2019
NCPE assessment completed 14/06/2019
NCPE assessment outcome The NCPE recommends that levodopa and carbidopa intestinal gel (Duodopa®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.  This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.